Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome
Objectives. Circulating IgG antibodies to oxidized low-density lipoprotein (anti-oxLDL) have been implicated in the development of atherosclerotic plaques. In this study, we investigated the prognostic value of IgG anti-oxLDL antibodies in patients with acute coronary syndrome (ACS). Methods. In tot...
Gespeichert in:
| Veröffentlicht in: | Lupus 2011-06, Vol.20 (7), p.730-735 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 735 |
|---|---|
| container_issue | 7 |
| container_start_page | 730 |
| container_title | Lupus |
| container_volume | 20 |
| creator | Laczik, R Szodoray, P Veres, K Szomják, E Csípő, I Sipka, S Shoenfeld, Y Szekanecz, Z Soltész, P |
| description | Objectives. Circulating IgG antibodies to oxidized low-density lipoprotein (anti-oxLDL) have been implicated in the development of atherosclerotic plaques. In this study, we investigated the prognostic value of IgG anti-oxLDL antibodies in patients with acute coronary syndrome (ACS). Methods. In total 54 patients with ACS and 41 matched healthy controls were involved in this prospective study. Serum IgG anti-oxLDL levels were assessed by ELISA. Results. Higher IgG anti-oxLDL levels were found in patients with ACS versus controls (22.8 ± 23.3 vs. 7.5 ± 5.27 EU/ml, p |
| doi_str_mv | 10.1177/0961203311398884 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_902366702</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0961203311398884</sage_id><sourcerecordid>875720018</sourcerecordid><originalsourceid>FETCH-LOGICAL-c395t-f878f9ea83e8b54273c2199c2204a385ac9d980d1b7047a3edb8894c2d2b860e3</originalsourceid><addsrcrecordid>eNqFkU1P3DAQhi1EBdtt7z0hiwun0LGdxOMjokCRVuqlnCPHnlCjTbzEiVr49Xi1fEhIFZcZaeaZdzTzMvZNwKkQWn8HUwsJSgmhDCKWe2whSq2LXJf7bLFtF9v-Ifuc0h0AKGHqA3YoRQUVCLFgN2cpUUo9DROPHb--veJ2mEIbfaDEp8jjv-DDI3m--rHiYeAbO4UMJ_43TH-4dfNE3MUxDnZ84Olh8GPs6Qv71Nl1oq_PecluLi9-n_8sVr-urs_PVoVTppqKDjV2hiwqwrYqpVZOCmOclFBahZV1xhsEL1oNpbaKfItoSie9bLEGUkt2stPdjPF-pjQ1fUiO1ms7UJxTY0CqutY5fkSirrQEEJjJ43fkXZzHIZ_RYI0VYJ2_vWSwg9wYUxqpazZj6PMLGgHN1prmvTV55OhZd2578q8DL15koNgByd7S29L_Cj4BGsOUDQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>868508611</pqid></control><display><type>article</type><title>Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome</title><source>Access via SAGE</source><source>MEDLINE</source><creator>Laczik, R ; Szodoray, P ; Veres, K ; Szomják, E ; Csípő, I ; Sipka, S ; Shoenfeld, Y ; Szekanecz, Z ; Soltész, P</creator><creatorcontrib>Laczik, R ; Szodoray, P ; Veres, K ; Szomják, E ; Csípő, I ; Sipka, S ; Shoenfeld, Y ; Szekanecz, Z ; Soltész, P</creatorcontrib><description>Objectives. Circulating IgG antibodies to oxidized low-density lipoprotein (anti-oxLDL) have been implicated in the development of atherosclerotic plaques. In this study, we investigated the prognostic value of IgG anti-oxLDL antibodies in patients with acute coronary syndrome (ACS). Methods. In total 54 patients with ACS and 41 matched healthy controls were involved in this prospective study. Serum IgG anti-oxLDL levels were assessed by ELISA. Results. Higher IgG anti-oxLDL levels were found in patients with ACS versus controls (22.8 ± 23.3 vs. 7.5 ± 5.27 EU/ml, p < 0.0001). IgG anti-oxLDL concentrations were significantly higher in ACS patients with unstable clinical complications (circulatory insufficiency, malignant arrhythmias, recurring ischaemic pain, positive stress-test, need for urgent coronary intervention or sudden cardiac death) versus those without such complications (30.0 vs. 11.7 EU/ml, p < 0.001). Twelve patients (22%) were taking statins. Patients on statins had a significant reduction in clinical complications (33%) versus patients not receiving statin therapy (61%). IgG anti-oxLDL levels were also different in these two groups (11.4 vs. 25.8 EU/ml, respectively; p = 0.03). Serum IgG anti-oxLDL levels correlated with the subsequent development of unstable coronary events. Levels of anti-oxLDL significantly decreased in response to statin therapy, independently of its lipid-lowering effect. Conclusions. Anti-oxLDL antibodies are involved in ACS. The association of anti-oxLDL with unstable clinical complications may indicate the role of this antibody in plaque destabilization.</description><identifier>ISSN: 0961-2033</identifier><identifier>EISSN: 1477-0962</identifier><identifier>DOI: 10.1177/0961203311398884</identifier><identifier>PMID: 21505011</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Acute Coronary Syndrome - blood ; Acute Coronary Syndrome - drug therapy ; Acute Coronary Syndrome - immunology ; Acute coronary syndromes ; Adult ; Aged ; Antibodies ; Arrhythmia ; Arteriosclerosis ; Atherosclerosis ; Autoantibodies - immunology ; Case-Control Studies ; Enzyme-Linked Immunosorbent Assay ; Female ; Heart ; Heart attacks ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology ; Immunoglobulin G ; Immunoglobulin G - blood ; Immunology ; Internal medicine ; Lipids ; Lipoproteins ; Lipoproteins (low density) ; Lipoproteins, LDL - immunology ; Male ; Medicine ; Middle Aged ; Pain ; Plaque, Atherosclerotic - immunology ; Plaques ; Prognosis ; Prospective Studies ; Science ; Statins</subject><ispartof>Lupus, 2011-06, Vol.20 (7), p.730-735</ispartof><rights>The Author(s), 2011. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</rights><rights>SAGE Publications © Jun 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c395t-f878f9ea83e8b54273c2199c2204a385ac9d980d1b7047a3edb8894c2d2b860e3</citedby><cites>FETCH-LOGICAL-c395t-f878f9ea83e8b54273c2199c2204a385ac9d980d1b7047a3edb8894c2d2b860e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0961203311398884$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0961203311398884$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>315,782,786,21826,27931,27932,43628,43629</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21505011$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Laczik, R</creatorcontrib><creatorcontrib>Szodoray, P</creatorcontrib><creatorcontrib>Veres, K</creatorcontrib><creatorcontrib>Szomják, E</creatorcontrib><creatorcontrib>Csípő, I</creatorcontrib><creatorcontrib>Sipka, S</creatorcontrib><creatorcontrib>Shoenfeld, Y</creatorcontrib><creatorcontrib>Szekanecz, Z</creatorcontrib><creatorcontrib>Soltész, P</creatorcontrib><title>Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome</title><title>Lupus</title><addtitle>Lupus</addtitle><description>Objectives. Circulating IgG antibodies to oxidized low-density lipoprotein (anti-oxLDL) have been implicated in the development of atherosclerotic plaques. In this study, we investigated the prognostic value of IgG anti-oxLDL antibodies in patients with acute coronary syndrome (ACS). Methods. In total 54 patients with ACS and 41 matched healthy controls were involved in this prospective study. Serum IgG anti-oxLDL levels were assessed by ELISA. Results. Higher IgG anti-oxLDL levels were found in patients with ACS versus controls (22.8 ± 23.3 vs. 7.5 ± 5.27 EU/ml, p < 0.0001). IgG anti-oxLDL concentrations were significantly higher in ACS patients with unstable clinical complications (circulatory insufficiency, malignant arrhythmias, recurring ischaemic pain, positive stress-test, need for urgent coronary intervention or sudden cardiac death) versus those without such complications (30.0 vs. 11.7 EU/ml, p < 0.001). Twelve patients (22%) were taking statins. Patients on statins had a significant reduction in clinical complications (33%) versus patients not receiving statin therapy (61%). IgG anti-oxLDL levels were also different in these two groups (11.4 vs. 25.8 EU/ml, respectively; p = 0.03). Serum IgG anti-oxLDL levels correlated with the subsequent development of unstable coronary events. Levels of anti-oxLDL significantly decreased in response to statin therapy, independently of its lipid-lowering effect. Conclusions. Anti-oxLDL antibodies are involved in ACS. The association of anti-oxLDL with unstable clinical complications may indicate the role of this antibody in plaque destabilization.</description><subject>Acute Coronary Syndrome - blood</subject><subject>Acute Coronary Syndrome - drug therapy</subject><subject>Acute Coronary Syndrome - immunology</subject><subject>Acute coronary syndromes</subject><subject>Adult</subject><subject>Aged</subject><subject>Antibodies</subject><subject>Arrhythmia</subject><subject>Arteriosclerosis</subject><subject>Atherosclerosis</subject><subject>Autoantibodies - immunology</subject><subject>Case-Control Studies</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Heart</subject><subject>Heart attacks</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulin G - blood</subject><subject>Immunology</subject><subject>Internal medicine</subject><subject>Lipids</subject><subject>Lipoproteins</subject><subject>Lipoproteins (low density)</subject><subject>Lipoproteins, LDL - immunology</subject><subject>Male</subject><subject>Medicine</subject><subject>Middle Aged</subject><subject>Pain</subject><subject>Plaque, Atherosclerotic - immunology</subject><subject>Plaques</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Science</subject><subject>Statins</subject><issn>0961-2033</issn><issn>1477-0962</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkU1P3DAQhi1EBdtt7z0hiwun0LGdxOMjokCRVuqlnCPHnlCjTbzEiVr49Xi1fEhIFZcZaeaZdzTzMvZNwKkQWn8HUwsJSgmhDCKWe2whSq2LXJf7bLFtF9v-Ifuc0h0AKGHqA3YoRQUVCLFgN2cpUUo9DROPHb--veJ2mEIbfaDEp8jjv-DDI3m--rHiYeAbO4UMJ_43TH-4dfNE3MUxDnZ84Olh8GPs6Qv71Nl1oq_PecluLi9-n_8sVr-urs_PVoVTppqKDjV2hiwqwrYqpVZOCmOclFBahZV1xhsEL1oNpbaKfItoSie9bLEGUkt2stPdjPF-pjQ1fUiO1ms7UJxTY0CqutY5fkSirrQEEJjJ43fkXZzHIZ_RYI0VYJ2_vWSwg9wYUxqpazZj6PMLGgHN1prmvTV55OhZd2578q8DL15koNgByd7S29L_Cj4BGsOUDQ</recordid><startdate>201106</startdate><enddate>201106</enddate><creator>Laczik, R</creator><creator>Szodoray, P</creator><creator>Veres, K</creator><creator>Szomják, E</creator><creator>Csípő, I</creator><creator>Sipka, S</creator><creator>Shoenfeld, Y</creator><creator>Szekanecz, Z</creator><creator>Soltész, P</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>201106</creationdate><title>Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome</title><author>Laczik, R ; Szodoray, P ; Veres, K ; Szomják, E ; Csípő, I ; Sipka, S ; Shoenfeld, Y ; Szekanecz, Z ; Soltész, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c395t-f878f9ea83e8b54273c2199c2204a385ac9d980d1b7047a3edb8894c2d2b860e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Acute Coronary Syndrome - blood</topic><topic>Acute Coronary Syndrome - drug therapy</topic><topic>Acute Coronary Syndrome - immunology</topic><topic>Acute coronary syndromes</topic><topic>Adult</topic><topic>Aged</topic><topic>Antibodies</topic><topic>Arrhythmia</topic><topic>Arteriosclerosis</topic><topic>Atherosclerosis</topic><topic>Autoantibodies - immunology</topic><topic>Case-Control Studies</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Heart</topic><topic>Heart attacks</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulin G - blood</topic><topic>Immunology</topic><topic>Internal medicine</topic><topic>Lipids</topic><topic>Lipoproteins</topic><topic>Lipoproteins (low density)</topic><topic>Lipoproteins, LDL - immunology</topic><topic>Male</topic><topic>Medicine</topic><topic>Middle Aged</topic><topic>Pain</topic><topic>Plaque, Atherosclerotic - immunology</topic><topic>Plaques</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Science</topic><topic>Statins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Laczik, R</creatorcontrib><creatorcontrib>Szodoray, P</creatorcontrib><creatorcontrib>Veres, K</creatorcontrib><creatorcontrib>Szomják, E</creatorcontrib><creatorcontrib>Csípő, I</creatorcontrib><creatorcontrib>Sipka, S</creatorcontrib><creatorcontrib>Shoenfeld, Y</creatorcontrib><creatorcontrib>Szekanecz, Z</creatorcontrib><creatorcontrib>Soltész, P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Lupus</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Laczik, R</au><au>Szodoray, P</au><au>Veres, K</au><au>Szomják, E</au><au>Csípő, I</au><au>Sipka, S</au><au>Shoenfeld, Y</au><au>Szekanecz, Z</au><au>Soltész, P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome</atitle><jtitle>Lupus</jtitle><addtitle>Lupus</addtitle><date>2011-06</date><risdate>2011</risdate><volume>20</volume><issue>7</issue><spage>730</spage><epage>735</epage><pages>730-735</pages><issn>0961-2033</issn><eissn>1477-0962</eissn><abstract>Objectives. Circulating IgG antibodies to oxidized low-density lipoprotein (anti-oxLDL) have been implicated in the development of atherosclerotic plaques. In this study, we investigated the prognostic value of IgG anti-oxLDL antibodies in patients with acute coronary syndrome (ACS). Methods. In total 54 patients with ACS and 41 matched healthy controls were involved in this prospective study. Serum IgG anti-oxLDL levels were assessed by ELISA. Results. Higher IgG anti-oxLDL levels were found in patients with ACS versus controls (22.8 ± 23.3 vs. 7.5 ± 5.27 EU/ml, p < 0.0001). IgG anti-oxLDL concentrations were significantly higher in ACS patients with unstable clinical complications (circulatory insufficiency, malignant arrhythmias, recurring ischaemic pain, positive stress-test, need for urgent coronary intervention or sudden cardiac death) versus those without such complications (30.0 vs. 11.7 EU/ml, p < 0.001). Twelve patients (22%) were taking statins. Patients on statins had a significant reduction in clinical complications (33%) versus patients not receiving statin therapy (61%). IgG anti-oxLDL levels were also different in these two groups (11.4 vs. 25.8 EU/ml, respectively; p = 0.03). Serum IgG anti-oxLDL levels correlated with the subsequent development of unstable coronary events. Levels of anti-oxLDL significantly decreased in response to statin therapy, independently of its lipid-lowering effect. Conclusions. Anti-oxLDL antibodies are involved in ACS. The association of anti-oxLDL with unstable clinical complications may indicate the role of this antibody in plaque destabilization.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>21505011</pmid><doi>10.1177/0961203311398884</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0961-2033 |
| ispartof | Lupus, 2011-06, Vol.20 (7), p.730-735 |
| issn | 0961-2033 1477-0962 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_902366702 |
| source | Access via SAGE; MEDLINE |
| subjects | Acute Coronary Syndrome - blood Acute Coronary Syndrome - drug therapy Acute Coronary Syndrome - immunology Acute coronary syndromes Adult Aged Antibodies Arrhythmia Arteriosclerosis Atherosclerosis Autoantibodies - immunology Case-Control Studies Enzyme-Linked Immunosorbent Assay Female Heart Heart attacks Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology Immunoglobulin G Immunoglobulin G - blood Immunology Internal medicine Lipids Lipoproteins Lipoproteins (low density) Lipoproteins, LDL - immunology Male Medicine Middle Aged Pain Plaque, Atherosclerotic - immunology Plaques Prognosis Prospective Studies Science Statins |
| title | Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T17%3A22%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessment%20of%20IgG%20antibodies%20to%20oxidized%20LDL%20in%20patients%20with%20acute%20coronary%20syndrome&rft.jtitle=Lupus&rft.au=Laczik,%20R&rft.date=2011-06&rft.volume=20&rft.issue=7&rft.spage=730&rft.epage=735&rft.pages=730-735&rft.issn=0961-2033&rft.eissn=1477-0962&rft_id=info:doi/10.1177/0961203311398884&rft_dat=%3Cproquest_cross%3E875720018%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=868508611&rft_id=info:pmid/21505011&rft_sage_id=10.1177_0961203311398884&rfr_iscdi=true |